IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
IceCure Medical (ICCM) added Legacy Health in Portland, OR, as a new U.S. clinical site for its ChoICE Study, evaluating ProSense® cryoablation for low-risk breast cancer. The study, approved by the FDA, aims to enroll 400 patients across 30 sites. Dr. Nathalie Johnson will lead the site's participation. IceCure's ProSense® is the only FDA-cleared device for this treatment in specific patients.
How this was made
The 30-second read
Why it matters
Adding a new site increases patient enrollment capacity, supporting data collection for future regulatory or reimbursement submissions.
Market read
The announcement is a modest, positive catalyst for IceCure, but unlikely to drive significant short‑term price movement.
What to watch
Potential regulatory or reimbursement hurdles could limit commercial uptake despite broader enrollment.
Background
IceCure Medical develops cryoablation devices; the ChoICE Study is a post‑market FDA‑approved trial to gather real‑world data on its ProSense® system for low‑risk breast cancer.
Ticker impact
IceCure Medical announced the addition of Legacy Health in Portland as a new U.S. clinical site for its post‑marketing ChoICE Study on ProSense® cryoablation for low‑risk breast cancer.
likely modest upside as investors price in broader trial enrollment and data generation
Clinical‑trial expansion is a positive catalyst but the immediate market impact is limited; the news is new but scale is modest.
Market effects
May reinforce confidence in minimally invasive cryoablation technologies within the med‑tech sector.
Limited to U.S. biotech/med‑tech investors; no broad regional effect.
Minimal global impact; primarily relevant to IceCure shareholders.
Counterpoint
The trial expansion may not translate into commercial revenue if later-phase data are inconclusive.
Key entities
- companyIceCure Medical Ltd.
Developer of the ProSense® cryoablation system, ticker ICCM.
- institutionLegacy Health
Non‑profit health system in Oregon adding a clinical site for the ChoICE Study.
